Replies to post #204611 on Biotech Values

[DewDiligence]

This would allow biotech investors to develop their own portfolios of single-drug cash flow streams rather than being forced to accept the ad hoc portfolios that big pharma have built over the years.

I don't follow how splitting up companies would enable investors to obtain such flexibility—please elaborate.